Collaborators

Morehouse School of Medicine (MSM), Collaborating Institution

Morehouse-SOM-LogoMorehouse School of Medicine (MSM), located in Atlanta, Ga., was founded in 1975 as the Medical Education Program at Morehouse College. In 1981, MSM became an independently chartered institution. MSM is among the nation’s leading educators of primary care physicians and was recently recognized as the top institution among U.S. medical schools for our social mission. Its faculty and alumni are noted in their fields for excellence in teaching, research and public policy.

James W. Lillard, Jr., Ph.D., MBA, Collaborating Investigator

Dr.  Lillard is an Associate Dean for Research at the Morehouse School of Medicine (MSM), the Director of the MSM’s Cancer Research Program, and a Professor in the MSM Departments of Microbiology, Biochemistry & Immunology. Lillard is an immuno-biologist who uses both in silico and in vivo methods to develop biologics, humanized antibodies, vaccines, and nanoparticles to diagnose and treat (prostate, breast, colon, ovarian, lung, and hepatocelluar) cancers and infectious diseases. His research contributions span multiple disciplines including oncology, vaccine development, biodefense, and neuro-inflammation. Dr. Lillard’s cumulative peer-reviewed funding principally directed over his scientific career exceeds $22m and he has authored over 320 scientific communications, which have been cited over 3,000 times.

Methode Bacanamwo, Ph.D., Collaborating Investigator

Dr.  Bacanamwo’s laboratory is interested in understanding the role of chromatin remodeling and epigenetic mechanisms in gene expression regulation during the pathogenesis of cardiovascular diseases and the differentiation of vascular cells from stem cells.  The long term objective of his research is to develop epigenetic and other novel therapeutic and diagnostic strategies useful for the prevention and treatment of cardiovascular disease. Dr. Bacanamwo’s team established that vascular cell differentiation, vascular cell fate determination, and vascular function and lesion formation, can be modulated by the manipulation of DNA methyltransferases, histone methyltransferases and demethylases, as well as histone acetyltransferases and deacetylases. Dr. Bacanamwo’s resources and expertise are being applied to the manipulation of cell populations identified by Haplomics as appropriate for use in its ex vivo gene repair protocols for HA. Dr. Bacanamwo’s lab is closely collaborating with Haplomics on cell based and in vivo (Hemophilia A dog) studies aimed at curing hemophilia.